The third batch of drug centralized procurement catalogue gradually became clear.

Pharmaceutical Network July 23 - On the evening of July 21, Shanghai Sunshine Pharmaceutical Procurement Network issued a "notice on the start of some of the basic information collection work of drugs" (hereinafter referred to as "Notice"), meaning that the third batch of drug collection catalog statistics, reporting work has been officially started.
and the second batch of national collection is slightly different, this collection to change the previous state to collect the list, tender documents, and then the enterprise to prepare information, quotation and bidding practices.
add a touch before the official list comes out.
notice clearly stipulates that this information collection work is only used for research, not as a basis for the declaration of drug centralized procurement enterprises, the specific declaration of enterprise qualifications and the declaration of varieties of eligibility to the procurement documents.
in other words, these 86 drugs are not the final catalogue of the third batch of drugs.
based on the previous collection process, from the symposium to the release of official documents about 20 days, from the publication of tender documents, tender to the proposed bid published about 20 days.
, the collection documents are expected to be issued by August 10, the results of the winning bid by the end of August.
affects 56 varieties Involving 153 enterprises On November 15, 2018, the first batch of "4 plus 7" national drug centralized procurement started, lasted 32 days, involving 25 varieties; On the 5th, the "4 plus 7" expansion came, lasted 46 days, involving 25 varieties, and on December 6, 2019, the second batch of national collection work began, lasted 46 days, involving 32 varieties.
and the collection of more varieties than before, reached 56.
As of July 21, 153 companies had been involved in 86 companies that met the conditions for collection, according to insight.
, including more varieties of enterprises are China Biopharmaceuticals (Hong Kong stock 01177), Shanghai Pharma (Hong Kong stock 02607), Yangzijiang, they were included in the number of varieties reached 9, 8, 7.
and stone medicine, Howson, HengRui, Qilu are included in the six varieties.
foreign enterprises, a total of more than 20 foreign enterprises have related varieties in the current directory.
Pfizer, Mercado, Novartis, AstraZeneca and other multinational pharmaceutical giants were included in the variety of 5, 5, 4, 3.
is behind the inclusion of more and more varieties in the collection, which bodes well for the inevitable price war between enterprises in the future.
data show that the first two batches of national shipments involving a total of 57 varieties, drug costs from 42.7 billion yuan to 8.3 billion yuan, saving 34.4 billion yuan.
the second batch of volume procurement results announced in January this year, the total amount of the volume of procurement is about 2.157 billion yuan, an average price reduction of 55%.
a pharmaceutical company sales representative in the Central Plains region told reporters, "the average price reduction of a new round of collection will not reach 60% I am not sure, but 55% of the price reduction must be more than."
from this catalog, due to the large number of products, the number of foreign companies involved in the competition, the third collection situation may be more exciting than before.
and, in July 20 to August 20 around, there will be a lot of enterprises review, the competitive landscape is changing at all times, deer dead who have to see.
"metformin led by more than 1 billion varieties of mido net data show that 56 generic drugs in 2019 In China's public medical institutions terminal total sales of more than 56 billion yuan, of which 23 drug sales of more than 1 billion yuan.
2019, the total sales of multiple dosage forms in public medical terminals in China amounted to 5.38 billion yuan, the sales of fentan ysatan in 2019 were 4.964 billion yuan, the sales of Capetabine was 3.49 billion yuan, and the sales of multiple dosings of cephalosporine reached 3.19 billion yuan.
metformin, which was out at the last minute in the second set, is the most interesting.
as China's oral blood glucose regulating drug market share of the second-ranked drug, metformin market share after acapolsugar, accounting for about 19%.
and this time it's more competitive than you can imagine.
at present, the number of enterprises rated by oral permanent release agent (0.25g, 0.5g) of metformin has 26, and the number of enterprises rated for metformin slow release control release agent (0.5g) has 16.
known as the "Group of Death" because of its large number of competitors.
how competitive the drug will be? In November 2019, Hebei Province issued a document for 15 kinds of urban and rural residents of hypertension, diabetes outpatient drugs for collection, metformin oral frequently released agents are expected to purchase 500 million tablets.
's winning documents show that the final winning stone drug Europa hydrochloride tablets (0.5g) price fell to 0.043 yuan / piece.
the price is 57.9% lower than its maximum price of 0.102 yuan per chip.
and stone drugs can be so price-to-price because its hydrochloric acid metformin raw materials for the group's own production.
this competitive advantage also makes the stone drug's acetate hydrochloride tablets as early as August 9, 2018 on the first evaluation.
a large domestic API enterprise staff to reporters, "metformin was previously affected by the satan impurity event and did not in the second batch of collection catalog."
but this medicine domestic use of too many people, in the short term can not find alternative products, into the collection is not open, the future to see who has raw materials.
at present, the price of metformin is already very low.
some enterprises almost in the cost price a little higher, which means that after the collection of a lot of enterprises will directly give up competition.
"in addition to metformin, omeprazole is also nicknamed "the murder" of the group.
omeprazole is a super-large variety of digestive tract medications, clinically used in the stomach, duodenal ulcers, reflux esophagitis, etc., its world-highest sales once exceeded 6 billion U.S. dollars.
in this collection catalog, omeprazole intestinal capsules are included.
data show that omeprazole intestinal capsule 20mg this product size of about 1.5 billion yuan, 10mg also has 300 million yuan.
and metformin has a number of competitors of the pattern is different, omeprazole "big plate, less enterprise", the current competitive landscape of 5 to 4.
according to statistics, Changzhou four-drug pharmaceutical omeprazole intestinal capsules in China has nearly 65% of the market share.
in this collection, with Changzhou four pharmaceutical drugs directly compete will be Shandong Luoxin, Hainan Hailing, Yangzijiang and the original research AstraZeneca.
similar to omeprazole intestinal capsules is a 4 billion yuan annual sales of sodium hydrochloride sodium chloride injection, annual sales of 3 billion yuan of cephalosporini oral permanent release dosage form.
the former involves Tianjin Hong-Sun, Hainan Aiko, Bayer, the latter involves the National Pharmaceutical Group, Jiangsu Hausen, Andrei.
a pharmaceutical industry analyst commented to reporters, "Astellas as a foreign enterprise, the first few rounds of products are few, almost in the collection of exposed, the market is not familiar with its 'set'."
its product size is not small this time.
principle, foreign companies will fight for their heavy products, and small capacity will give up.
" foreign enterprises will face fierce competition for market share for a long time, imported drug prices are usually higher than domestic drugs, and in recent years, the collection of price cuts so that many foreign enterprises end the day of lying down to earn money.
in the current collection catalog, there have also been foreign enterprises once lie win varieties.
but now they have met a number of market to win the "crazy price" of domestic rivals.
, for example, the recital tablets and anaqueave.
they are oncology pipeline drugs for assisted treatment in postmenopausal early breast cancer patients.
data show that total global sales of $565 million in 2018 have brought novartis a significant return.
this time will compete with Novartis is the domestic pharmaceutical industry's current "one brother" Heng Rui and once with its name of Haizheng.
interesting, on November 6, 2019, Heng Rui and Hai Zheng announced their review of the film on the same day.
current, Novartis's tablet price is 34.87 yuan / piece, while Hengrui and Hai Zheng get the price of only 10.49 yuan / piece and 9.11 yuan / piece.
a pharmaceutical industry analyst told reporters, "The qurandis is over a billion levels of large varieties."
the current 3 into 2, the number of competing enterprises is small, not a full competition situation, but also does not mean that the price war is not ringing.
Novartis this product if you want to enter the collection, estimated to bleed.
" Minet data show that in 2018 in China's public medical institutions terminal to the sale of rice tablets more than 2 billion yuan.
, Novartis has a market share of 58.39 percent, Hengrui 39.35 percent and Haizheng 2.26 percent.
the market advantage of the original research of Anaqua tablets is equally adequate, more than 80% of the market by the original research enterprise AstraZeneca occupied, Yangzijiang market share is the second, but only about 8%.
currently, in addition to AstraZeneca and Yangzijiang, Haizheng and Huabang are also in the competition.
in January of this year's Fujian collection, AstraZeneca's latest bid price of 29.93 yuan / piece, but Chongqing Huabang bid 9.58 yuan / piece, a third of AstraZeneca, and Haizheng even opened 7.72 yuan / film, the degree of competition can be seen.
, in addition, the reporter noted that the current collection catalog, there are more "new drugs."
, for example, apixaban.
Apaishaban is a new generation of oral anticoagulants, its domestic market is still in the long-term, annual sales of less than 100 million yuan.
however, the drug had global sales of $7.4 billion in 2017 and was the world's runner-up in drug sales in 2018, behind Adamum.
similar situations are left-handed lasitan, Viglitin and so on.
industry insiders believe that such products rise space is larger, the current collection or for the future competitive landscape, the relevant enterprise layout is worth looking forward to.
.